University of Surrey

Test tubes in the lab Research in the ATI Dance Research

Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction

Latifoltojar, A, Hall-Craggs, M, Bainbridge, A, Yong, K, Dikaios, Nikolaos, Sokolska, M, Rabin, N, Antonelli, M, Ourselin, S, Popat, R , Rismani, A, D’Sa, S, Taylor, S, Halligan, S and Punwani, S (2017) Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction European Radiology, 27 (12). pp. 5325-5336.

[img]
Preview
Text
10.1007%2Fs00330-017-4907-8.pdf - Version of Record

Download (3MB) | Preview
[img] Text
Whole-body MRI quantitative biomarkers predict response in patients with newly diagnosed symptomatic mm following Bortezomib induction (002).pdf - Accepted version Manuscript
Restricted to Repository staff only

Download (3MB)

Abstract

Purpose: To evaluate whole-body MRI (WB-MRI) parameters for treatment response prediction in multiple myeloma (MM). Materials and Methods: Twenty-one MM patients underwent WB-MRI at diagnosis and after 2 cycles of chemotherapy. Scans acquired at 3.0T included T2, diffusionweighted- imaging (DWI) and mDixon pre- and post-contrast. Twenty focal lesions (FLs) matched on DWI and enhanced mDixon were selected for each time point. Estimated tumour volume (eTV), apparentdiffusion- coefficient (ADC), enhancement-ratio (ER) and signal fat fraction (sFF) were derived. Clinical treatment response to chemotherapy was assessed using conventional criteria. Significance of temporal parameter change was assessed by the paired t-test and receiver operating characteristics/area under the curve (AUC) analysis was performed. Parameter repeatability was assessed by interclass correlation (ICC) and Bland-Altman analysis of 10 healthy volunteers scanned at two time-points. Results: 15/21 patients responded to treatment. Of 254 FLs analysed, sFF (p<0.0001) and ADC (p=0.001) significantly increased in responders but not non-responders. eTV significantly decreased in 20/21 cases. Focal lesion sFF was the best predictor of treatment response (AUC 1.0). Bone sFF repeatability was excellent (ICC 0.98 ) and better than bone ADC (ICC 0.47). Conclusion: WB-MRI derived focal lesion sFF shows promise as an imaging biomarker of treatment response in newly diagnosed MM.

Item Type: Article
Divisions : Faculty of Engineering and Physical Sciences > Electronic Engineering
Authors :
NameEmailORCID
Latifoltojar, A
Hall-Craggs, M
Bainbridge, A
Yong, K
Dikaios, Nikolaosn.dikaios@surrey.ac.uk
Sokolska, M
Rabin, N
Antonelli, M
Ourselin, S
Popat, R
Rismani, A
D’Sa, S
Taylor, S
Halligan, S
Punwani, S
Date : 27 June 2017
Funders : CRUK/EPSRC
Identification Number : 10.1007/s00330-017-4907-8
Copyright Disclaimer : Copyright The Author(s) 2017. This article is an open access publication.
Uncontrolled Keywords : MRI, Whole Body, Multiple Myeloma, Bortezomib Response Monitoring
Depositing User : Melanie Hughes
Date Deposited : 23 May 2017 16:58
Last Modified : 05 Jan 2018 10:48
URI: http://epubs.surrey.ac.uk/id/eprint/841089

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year


Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800